Full-Time

Director – National Accounts

Confirmed live in the last 24 hours

Axsome Therapeutics Inc

Axsome Therapeutics Inc

201-500 employees

Develops therapies for CNS disorders

Biotechnology
Healthcare

Compensation Overview

$200k - $235kAnnually

+ Bonus + Equity

Senior

New York, NY, USA

Category
Strategic Account Management
Sales & Account Management
Required Skills
Marketing
Requirements
  • Bachelor's degree in business, marketing, economics, or health sciences
  • Minimum of 6 years of successful Payer Account Management experience required
  • Strong understanding of the payer landscape and how payer decision making impacts providers and their patients
  • Demonstrated experience gaining formulary access for a launch product at national payer and PBM, as well as key regional, accounts
Responsibilities
  • Ensure disciplined and effective communication with key payer stakeholders and decision makers
  • Understand dynamics of Payer (PBM and Plan) relationships, and key decision makers
  • Network across the industry and each account
  • Execute the payer engagement strategy and leverage Payer Value Proposition to obtain appropriate access/formulary position among target accounts
  • Profile key payer accounts to assess formulary review process, formulary coverage policies, utilization management deployed for the applicable therapeutic areas, and geographic coverage areas
  • Identify and address potential barriers to access proactively to ensure launch product is well positioned for formulary and P&T reviews
  • Identify competitive threats and develop strategies to ensure optimal coverage for Axsome Therapeutics’ portfolio of products
  • Lead pull-though initiatives that capitalize on formulary wins and lead push-though efforts in areas with access challenges
  • Ensure compliance with Axsome Therapeutics’ corporate policies and procedures and U.S. healthcare laws and regulations
Axsome Therapeutics Inc

Axsome Therapeutics Inc

View

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain to help regulate mood. This drug has shown positive results in clinical trials and has received FDA Breakthrough Therapy Designation, which helps speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

Company Stage

IPO

Total Funding

$430.7M

Headquarters

New York City, New York

Founded

2012

Growth & Insights
Headcount

6 month growth

3%

1 year growth

3%

2 year growth

3%
Simplify Jobs

Simplify's Take

What believers are saying

  • The launch of Auvelity and the promising results of AXS-12 in Phase 3 trials indicate strong potential for revenue growth and market impact.
  • Axsome's strategic expansion of its sales force to support Auvelity's launch demonstrates its commitment to commercial success.
  • The appointment of experienced leaders like Dr. Sue Mahony to the board enhances Axsome's strategic direction and governance.

What critics are saying

  • The biopharmaceutical sector's inherent risks, including regulatory hurdles and clinical trial failures, could impact Axsome's progress.
  • High competition in the CNS disorder treatment market may challenge Axsome's ability to capture significant market share.

What makes Axsome Therapeutics Inc unique

  • Axsome Therapeutics focuses on CNS disorders with a strong emphasis on unmet medical needs, setting it apart from broader biopharmaceutical companies.
  • The FDA Breakthrough Therapy Designation for AXS-05 highlights its innovative approach and potential for rapid market entry.
  • Axsome's diversified pipeline, including treatments for MDD, TRD, Alzheimer's agitation, and narcolepsy, showcases its comprehensive strategy in CNS therapeutics.

Help us improve and share your feedback! Did you find this helpful?